Synonyms: GSK3335065 | inhibitor C1 [PMID: 28604669]
Compound class:
Synthetic organic
Comment: GSK065 (a.k.a. GSK3335065) was a clinical lead kynurenine-3-monooxygenase (KMO) inhibitor that was developed for potential to treat acute pancreatitis multiple organ dysfunction syndrome (AP-MODS) [1]. It was designed to be administered intravenously. The intention of inhibiting KMO is to return AP-MODS-associated elevation in 3-hydroxykynurenine levels [2] to the normal range, so as to reduce acute pancreatitis-induced organ damage. GSK065 was developed though a partnership between the University of Edinburgh's Centre for Inflammation Research and GSK's Discovery Partnerships with Academia programme.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|